12 analysts have expressed a variety of opinions on Aspen Aerogels ASPN over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 1 | 0 | 0 | 0 |
| 2M Ago | 5 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $31.33, a high estimate of $38.00, and a low estimate of $22.00. This current average reflects an increase of 22.48% from the previous average price target of $25.58.
Analyzing Analyst Ratings: A Detailed Breakdown
The analysis of recent analyst actions sheds light on the perception of Aspen Aerogels by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Eric Stine | Craig-Hallum | Raises | Buy | $38.00 | $33.00 |
| Tom Curran | Seaport Global | Raises | Buy | $38.00 | $31.00 |
| Chip Moore | Roth MKM | Raises | Buy | $36.00 | $28.00 |
| Jeffrey Osborne | TD Cowen | Raises | Buy | $36.00 | $30.00 |
| Alexander Potter | Piper Sandler | Raises | Overweight | $36.00 | $30.00 |
| Alexander Potter | Piper Sandler | Raises | Overweight | $30.00 | $29.00 |
| George Gianarikas | Canaccord Genuity | Raises | Buy | $28.00 | $18.00 |
| Christopher Souther | B. Riley Securities | Raises | Buy | $30.00 | $24.00 |
| Chip Moore | Roth MKM | Raises | Buy | $28.00 | $22.00 |
| Alexander Potter | Piper Sandler | Raises | Overweight | $29.00 | $20.00 |
| Amit Dayal | HC Wainwright & Co. | Raises | Buy | $25.00 | $20.00 |
| Chip Moore | Roth MKM | Maintains | Buy | $22.00 | $22.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Aspen Aerogels. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Aspen Aerogels compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Aspen Aerogels's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Aspen Aerogels's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Aspen Aerogels analyst ratings.
Unveiling the Story Behind Aspen Aerogels
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.
Key Indicators: Aspen Aerogels's Financial Health
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Aspen Aerogels's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 107.3%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Aspen Aerogels's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Aspen Aerogels's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.37%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Aspen Aerogels's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.26%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.29.
The Core of Analyst Ratings: What Every Investor Should Know
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
